Epoch Investment Partners Inc. Reduces Position in CVS Health Corporation $CVS

Epoch Investment Partners Inc. reduced its position in CVS Health Corporation (NYSE:CVS) by 7.0% in the fourth quarter, Holdings Channel.com reports. The fund owned 2,094,935 shares of the pharmacy operator’s stock after selling 158,895 shares during the quarter. CVS Health makes up about 0.9% of Epoch Investment Partners Inc.’s holdings, making the stock its 23rd biggest holding. Epoch Investment Partners Inc.’s holdings in CVS Health were worth $166,254,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Adams Diversified Equity Fund Inc. grew its stake in CVS Health by 175.5% during the fourth quarter. Adams Diversified Equity Fund Inc. now owns 351,300 shares of the pharmacy operator’s stock valued at $27,879,000 after acquiring an additional 223,800 shares in the last quarter. Atlas Capital Advisors Inc. purchased a new position in CVS Health during the fourth quarter valued at approximately $2,955,000. Aptus Capital Advisors LLC grew its stake in CVS Health by 1.7% during the fourth quarter. Aptus Capital Advisors LLC now owns 15,060 shares of the pharmacy operator’s stock valued at $1,195,000 after acquiring an additional 246 shares in the last quarter. CreativeOne Wealth LLC grew its stake in CVS Health by 25.7% during the fourth quarter. CreativeOne Wealth LLC now owns 8,592 shares of the pharmacy operator’s stock valued at $682,000 after acquiring an additional 1,754 shares in the last quarter. Finally, Transamerica Financial Advisors LLC grew its stake in CVS Health by 113.9% during the fourth quarter. Transamerica Financial Advisors LLC now owns 894 shares of the pharmacy operator’s stock valued at $71,000 after acquiring an additional 476 shares in the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on CVS shares. Sanford C. Bernstein boosted their price objective on shares of CVS Health from $94.00 to $106.00 and gave the company an “outperform” rating in a research note on Tuesday, May 12th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of CVS Health from $88.00 to $92.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Wall Street Zen cut shares of CVS Health from a “buy” rating to a “hold” rating in a research report on Saturday. HSBC upped their price objective on shares of CVS Health from $83.00 to $85.00 and gave the stock a “hold” rating in a research report on Tuesday, May 5th. Finally, Piper Sandler restated an “overweight” rating and issued a $113.00 price objective on shares of CVS Health in a research report on Monday, June 1st. Twenty-two analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $100.68.

Insider Buying and Selling

In other news, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the sale, the executive vice president owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. This represents a 87.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Larry Robbins sold 1,983,538 shares of the stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total value of $187,345,164.10. Following the sale, the director directly owned 6,213,261 shares of the company’s stock, valued at approximately $586,842,501.45. This trade represents a 24.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 3,441,551 shares of company stock worth $323,703,977 over the last quarter. Company insiders own 0.85% of the company’s stock.

CVS Health Stock Up 1.4%

Shares of NYSE CVS opened at $101.87 on Friday. CVS Health Corporation has a one year low of $58.50 and a one year high of $102.77. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66. The firm’s 50 day simple moving average is $86.91 and its two-hundred day simple moving average is $80.78. The stock has a market capitalization of $129.98 billion, a P/E ratio of 44.88, a PEG ratio of 1.00 and a beta of 0.62.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The business had revenue of $100.43 billion for the quarter, compared to analysts’ expectations of $94.99 billion. During the same period last year, the business earned $2.25 earnings per share. The business’s quarterly revenue was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, analysts expect that CVS Health Corporation will post 7.44 EPS for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, May 4th. Shareholders of record on Thursday, April 23rd were given a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date was Thursday, April 23rd. CVS Health’s dividend payout ratio (DPR) is presently 117.18%.

More CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS is expanding access to GLP-1 weight-loss drugs, including bringing back Zepbound and loosening restrictions on newer oral therapies, which could improve customer engagement and prescription volume while supporting its broader healthcare platform. Is CVS (CVS) Using GLP-1 Access and AI Tools to Redefine Its Healthcare Moat?
• Positive Sentiment: The company is also pushing AI deeper into pharmacy, insurance, and care delivery operations, aiming to cut administrative burden, improve efficiency, and potentially widen margins over time. Healthy Returns: CVS Health executives on reducing health care’s biggest pain points
• Positive Sentiment: CVS Health has launched Aetna Mental Health on Demand, which gives members faster access to care and shows the company is trying to strengthen service offerings across its insurance business. 5 Low Price-to-Book Stocks That Are Worth Buying in June
• Positive Sentiment: Recent coverage notes CVS at a 52-week high and highlights strong post-earnings momentum, while screening screens and “trending stock” mentions suggest investor interest remains elevated. CVS Health Corporation (CVS) Hit a 52 Week High, Can the Run Continue?
• Neutral Sentiment: CVS is also working with Fluency to move autonomous AI agents from pilot projects into production, but the financial impact is still early and not yet quantified. CVS is Using Fluency to Close Enterprise AI Deployment Gap
• Neutral Sentiment: News that Mass General Brigham and CVS are moving closer to a primary care partnership and that the stock is being heavily discussed by retail investors adds attention, but these items are not immediate earnings drivers. Mass General Brigham and CVS primary care partnership moves closer to reality
• Negative Sentiment: Musab Balbale’s departure adds some leadership turnover, though the market may view it as a limited issue unless more executive changes follow. Musab Balbale Departs CVS Health

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.